Biosergen AB (publ) (OM: BIOSGN)
Health Care · Biotechnology · SE
Skr2.48
+19.23% today · -95.8% 1Y
Biosergen AB (publ) (OM: BIOSGN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $515.80K and employs 1 people.
Over the last twelve months the share price has lost 95.8%, trading between 0.70 and 55.20.
Tweenvest scores Biosergen AB (publ) across four factors: quality 26/100. Its strongest factor is quality.
BIOSGN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $515.80K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- -0.03
- 52-week high
- Skr55.20
- 52-week low
- Skr0.70
- Avg volume (3M)
- —
- Shares outstanding
- 2.35M
- Employees
- 1
- Next earnings
- —
About Biosergen AB (publ)
Biosergen AB is a biopharmaceutical company specializing in the creation of antifungal medications. Its key development initiative is BSG005, an experimental antifungal drug candidate engineered to treat critical invasive fungal infections. The firm was established in 2004 and operates from its headquarters located in Solna, Sweden.
- ISIN
- SE0026821852
- Founded
- 2004
- Listed since
- Jun 24, 2021
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.